Watson David O., General Counsel at Apellis Pharmaceuticals ($APLS), sold about $1.7 million in company shares across 11 open market transactions over the past year. His most recent sale occurred on January 22, 2026. These sales rank 3,838th among 11,678 individual insiders in our database, where the average is $8.6 million per seller over roughly 6.4 trades. He made no open market purchases in this period.
| Transaction Date | Company | Ticker | Insider Name | Title | Transaction Type | Security | Shares | Price | Shares Owned Following | Total Shares Outstanding | % of Owned | % of Outstanding |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Jan. 28, 2026 | Apellis Pharmaceuticals, Inc. | $APLS | Watson David O. | General Counsel | A | Common Stock | 55986 | $0.00 | 204,653.0000 | 130,067,000 | 37.66% | 0.04% |
| Jan. 22, 2026 | Apellis Pharmaceuticals, Inc. | $APLS | Watson David O. | General Counsel | S | Common Stock | 7832 | $21.77 | 148,667.0000 | 130,067,000 | 5.00% | 0.01% |
| Jan. 20, 2026 | Apellis Pharmaceuticals, Inc. | $APLS | Watson David O. | General Counsel | S | Common Stock | 2475 | $19.79 | 156,499.0000 | 130,067,000 | 1.56% | 0.00% |
| Jan. 13, 2026 | Apellis Pharmaceuticals, Inc. | $APLS | Watson David O. | General Counsel | S | Common Stock | 5780 | $22.19 | 158,974.0000 | 130,067,000 | 3.51% | 0.00% |
| Jan. 7, 2026 | Apellis Pharmaceuticals, Inc. | $APLS | Watson David O. | General Counsel | M | Stock Option (Right to Buy) | 888 | $0.00 | 14,000.0000 | 130,067,000 | 5.96% | 0.00% |
| Jan. 7, 2026 | Apellis Pharmaceuticals, Inc. | $APLS | Watson David O. | General Counsel | M | Common Stock | 888 | $14.95 | 164,754.0000 | 130,067,000 | 0.54% | 0.00% |
| Dec. 16, 2025 | Apellis Pharmaceuticals, Inc. | $APLS | Watson David O. | General Counsel | S | Common Stock | 5000 | $24.49 | 163,866.0000 | 130,067,000 | 2.96% | 0.00% |
| Nov. 17, 2025 | Apellis Pharmaceuticals, Inc. | $APLS | Watson David O. | General Counsel | S | Common Stock | 5000 | $20.06 | 168,866.0000 | 130,067,000 | 2.88% | 0.00% |
| Oct. 16, 2025 | Apellis Pharmaceuticals, Inc. | $APLS | Watson David O. | General Counsel | S | Common Stock | 5000 | $25.22 | 173,866.0000 | 130,067,000 | 2.80% | 0.00% |
| Sept. 16, 2025 | Apellis Pharmaceuticals, Inc. | $APLS | Watson David O. | General Counsel | S | Common Stock | 5000 | $24.34 | 178,866.0000 | 123,905,000 | 2.72% | 0.00% |
| Sept. 10, 2025 | Apellis Pharmaceuticals, Inc. | $APLS | Watson David O. | General Counsel | S | Common Stock | 20000 | $26.17 | 183,866.0000 | 123,905,000 | 9.81% | 0.02% |
| Aug. 18, 2025 | Apellis Pharmaceuticals, Inc. | $APLS | Watson David O. | General Counsel | S | Common Stock | 5000 | $27.80 | 203,866.0000 | 123,905,000 | 2.39% | 0.00% |
| July 16, 2025 | Apellis Pharmaceuticals, Inc. | $APLS | Watson David O. | General Counsel | S | Common Stock | 5000 | $19.55 | 208,866.0000 | 123,905,000 | 2.34% | 0.00% |
| June 16, 2025 | Apellis Pharmaceuticals, Inc. | $APLS | Watson David O. | General Counsel | S | Common Stock | 5000 | $18.77 | 213,866.0000 | 123,905,000 | 2.28% | 0.00% |
| June 9, 2025 | Apellis Pharmaceuticals, Inc. | $APLS | Watson David O. | General Counsel | A | Stock Option (Right to Buy) | 82500 | $19.39 | 82,500.0000 | 123,905,000 | 9999.99% | 0.07% |
| March 5, 2025 | Apellis Pharmaceuticals, Inc. | $APLS | Watson David O. | General Counsel | S | Common Stock | 5569 | $25.10 | 218,866.0000 | 123,905,000 | 2.48% | 0.00% |
| March 4, 2025 | Apellis Pharmaceuticals, Inc. | $APLS | Watson David O. | General Counsel | G | Common Stock | 6667 | $0.00 | 218,866.0000 | 123,905,000 | 2.96% | 0.01% |
| March 4, 2025 | Apellis Pharmaceuticals, Inc. | $APLS | Watson David O. | General Counsel | G | Common Stock | 6667 | $0.00 | 218,866.0000 | 123,905,000 | 3.14% | 0.01% |
| Jan. 29, 2025 | Apellis Pharmaceuticals, Inc. | $APLS | Watson David O. | General Counsel | S | Common Stock | 695 | $29.52 | 224,435.0000 | 123,905,000 | 0.31% | 0.00% |
| Jan. 22, 2025 | Apellis Pharmaceuticals, Inc. | $APLS | Watson David O. | General Counsel | S | Common Stock | 3323 | $30.43 | 225,130.0000 | 123,905,000 | 1.45% | 0.00% |
| Jan. 17, 2025 | Apellis Pharmaceuticals, Inc. | $APLS | Watson David O. | General Counsel | S | Common Stock | 2201 | $29.96 | 185,691.0000 | 123,905,000 | 1.17% | 0.00% |
| Jan. 21, 2025 | Apellis Pharmaceuticals, Inc. | $APLS | Watson David O. | General Counsel | A | Common Stock | 42762 | $0.00 | 228,453.0000 | 123,905,000 | 23.03% | 0.03% |
| Jan. 13, 2025 | Apellis Pharmaceuticals, Inc. | $APLS | Watson David O. | General Counsel | S | Common Stock | 4965 | $28.70 | 187,892.0000 | 123,905,000 | 2.57% | 0.00% |
| Dec. 11, 2024 | Apellis Pharmaceuticals, Inc. | $APLS | Watson David O. | General Counsel | S | Common Stock | 5000 | $34.24 | 192,857.0000 | 124,234,000 | 2.53% | 0.00% |
| Sept. 27, 2024 | Apellis Pharmaceuticals, Inc. | $APLS | Watson David O. | General Counsel | G | Common Stock | 10569 | $0.00 | 197,857.0000 | 118,678,000 | 5.64% | 0.01% |
| Sept. 27, 2024 | Apellis Pharmaceuticals, Inc. | $APLS | Watson David O. | General Counsel | G | Common Stock | 10569 | $0.00 | 197,857.0000 | 118,678,000 | 5.07% | 0.01% |
| March 6, 2024 | Apellis Pharmaceuticals, Inc. | $APLS | Watson David O. | General Counsel | M | Common Stock | 3762 | $13.85 | 197,857.0000 | 118,678,000 | 1.94% | 0.00% |
| March 6, 2024 | Apellis Pharmaceuticals, Inc. | $APLS | Watson David O. | General Counsel | M | Stock Option (Right to Buy) | 3762 | $0.00 | 0.0000 | 118,678,000 | 100.00% | 0.00% |
| Feb. 12, 2024 | Apellis Pharmaceuticals, Inc. | $APLS | Watson David O. | General Counsel | S | Common Stock | 781 | $67.77 | 194,095.0000 | 118,678,000 | 0.40% | 0.00% |
| Jan. 29, 2024 | Apellis Pharmaceuticals, Inc. | $APLS | Watson David O. | General Counsel | S | Common Stock | 906 | $64.14 | 194,876.0000 | 118,678,000 | 0.46% | 0.00% |
| Jan. 22, 2024 | Apellis Pharmaceuticals, Inc. | $APLS | Watson David O. | General Counsel | S | Common Stock | 4184 | $65.00 | 195,782.0000 | 118,678,000 | 2.09% | 0.00% |
| Jan. 16, 2024 | Apellis Pharmaceuticals, Inc. | $APLS | Watson David O. | General Counsel | A | Stock Option (Right to Buy) | 34533 | $66.30 | 34,533.0000 | 118,678,000 | 9999.99% | 0.03% |
| Jan. 16, 2024 | Apellis Pharmaceuticals, Inc. | $APLS | Watson David O. | General Counsel | A | Common Stock | 23748 | $0.00 | 204,206.0000 | 118,678,000 | 13.16% | 0.02% |
| Jan. 16, 2024 | Apellis Pharmaceuticals, Inc. | $APLS | Watson David O. | General Counsel | S | Common Stock | 4240 | $66.81 | 199,966.0000 | 118,678,000 | 2.08% | 0.00% |
| Dec. 19, 2023 | Apellis Pharmaceuticals, Inc. | $APLS | Watson David O. | General Counsel | M | Stock Option (Right to Buy) | 7905 | $0.00 | 3,762.0000 | 106,114,000 | 67.76% | 0.01% |
| Dec. 19, 2023 | Apellis Pharmaceuticals, Inc. | $APLS | Watson David O. | General Counsel | S | Common Stock | 2300 | $57.38 | 180,458.0000 | 106,114,000 | 1.26% | 0.00% |
| Dec. 19, 2023 | Apellis Pharmaceuticals, Inc. | $APLS | Watson David O. | General Counsel | S | Common Stock | 1605 | $57.00 | 182,758.0000 | 106,114,000 | 0.87% | 0.00% |
| Dec. 19, 2023 | Apellis Pharmaceuticals, Inc. | $APLS | Watson David O. | General Counsel | M | Common Stock | 7905 | $13.85 | 184,363.0000 | 106,114,000 | 4.48% | 0.01% |
| July 3, 2023 | Apellis Pharmaceuticals, Inc. | $APLS | Watson David O. | General Counsel | S | Common Stock | 8510 | $89.98 | 176,458.0000 | 106,114,000 | 4.60% | 0.01% |
| June 28, 2023 | Apellis Pharmaceuticals, Inc. | $APLS | Watson David O. | General Counsel | G | Common Stock | 12750 | $0.00 | 184,968.0000 | 106,114,000 | 7.40% | 0.01% |
| June 28, 2023 | Apellis Pharmaceuticals, Inc. | $APLS | Watson David O. | General Counsel | G | Common Stock | 12750 | $0.00 | 184,968.0000 | 106,114,000 | 6.45% | 0.01% |
| April 21, 2023 | Apellis Pharmaceuticals, Inc. | $APLS | Watson David O. | General Counsel | G | Common Stock | 67955 | $0.00 | 184,968.0000 | 106,114,000 | 58.07% | 0.06% |
| April 21, 2023 | Apellis Pharmaceuticals, Inc. | $APLS | Watson David O. | General Counsel | G | Common Stock | 67955 | $0.00 | 184,968.0000 | 106,114,000 | 26.87% | 0.06% |
| Feb. 21, 2023 | Apellis Pharmaceuticals, Inc. | $APLS | Watson David O. | General Counsel | F | Common Stock | 825 | $58.50 | 184,968.0000 | 106,114,000 | 0.44% | 0.00% |
| Feb. 21, 2023 | Apellis Pharmaceuticals, Inc. | $APLS | Watson David O. | General Counsel | A | Common Stock | 9886 | $0.00 | 185,793.0000 | 106,114,000 | 5.62% | 0.01% |
| Feb. 21, 2023 | Apellis Pharmaceuticals, Inc. | $APLS | Watson David O. | General Counsel | A | Stock Option (Right to Buy) | 14023 | $0.00 | 14,023.0000 | 106,114,000 | 9999.99% | 0.01% |
| Feb. 10, 2023 | Apellis Pharmaceuticals, Inc. | $APLS | Watson David O. | General Counsel | F | Common Stock | 532 | $51.21 | 175,907.0000 | 106,114,000 | 0.30% | 0.00% |
| Jan. 27, 2023 | Apellis Pharmaceuticals, Inc. | $APLS | Watson David O. | General Counsel | F | Common Stock | 551 | $52.77 | 176,439.0000 | 106,114,000 | 0.31% | 0.00% |
| Jan. 20, 2023 | Apellis Pharmaceuticals, Inc. | $APLS | Watson David O. | General Counsel | F | Common Stock | 2034 | $52.05 | 176,990.0000 | 106,114,000 | 1.14% | 0.00% |
| Jan. 12, 2023 | Apellis Pharmaceuticals, Inc. | $APLS | Watson David O. | General Counsel | A | Common Stock | 24003 | $0.00 | 149,572.0000 | 106,114,000 | 19.12% | 0.02% |
| Jan. 12, 2023 | Apellis Pharmaceuticals, Inc. | $APLS | Watson David O. | General Counsel | A | Stock Option (Right to Buy) | 37708 | $52.66 | 37,708.0000 | 106,114,000 | 9999.99% | 0.04% |
| Jan. 12, 2023 | Apellis Pharmaceuticals, Inc. | $APLS | Watson David O. | General Counsel | A | Common Stock | 29452 | $0.00 | 179,024.0000 | 106,114,000 | 19.69% | 0.03% |